![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MLKL |
Gene summary for MLKL |
![]() |
Gene information | Species | Human | Gene symbol | MLKL | Gene ID | 197259 |
Gene name | mixed lineage kinase domain like pseudokinase | |
Gene Alias | hMLKL | |
Cytomap | 16q23.1 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q8NB16 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
197259 | MLKL | P4T-E | Human | Esophagus | ESCC | 1.18e-02 | 1.52e-01 | 0.1323 |
197259 | MLKL | P11T-E | Human | Esophagus | ESCC | 1.93e-05 | 2.91e-01 | 0.1426 |
197259 | MLKL | P20T-E | Human | Esophagus | ESCC | 1.15e-03 | 9.61e-02 | 0.1124 |
197259 | MLKL | P21T-E | Human | Esophagus | ESCC | 1.66e-06 | 2.36e-01 | 0.1617 |
197259 | MLKL | P23T-E | Human | Esophagus | ESCC | 2.29e-03 | 1.47e-01 | 0.108 |
197259 | MLKL | P24T-E | Human | Esophagus | ESCC | 1.71e-12 | 1.25e-01 | 0.1287 |
197259 | MLKL | P26T-E | Human | Esophagus | ESCC | 8.87e-05 | 8.44e-02 | 0.1276 |
197259 | MLKL | P28T-E | Human | Esophagus | ESCC | 4.17e-03 | 1.05e-01 | 0.1149 |
197259 | MLKL | P32T-E | Human | Esophagus | ESCC | 4.71e-05 | 7.60e-02 | 0.1666 |
197259 | MLKL | P36T-E | Human | Esophagus | ESCC | 8.81e-08 | 1.96e-01 | 0.1187 |
197259 | MLKL | P48T-E | Human | Esophagus | ESCC | 2.19e-03 | 4.50e-02 | 0.0959 |
197259 | MLKL | P52T-E | Human | Esophagus | ESCC | 4.45e-12 | 3.41e-01 | 0.1555 |
197259 | MLKL | P62T-E | Human | Esophagus | ESCC | 3.56e-14 | 3.09e-01 | 0.1302 |
197259 | MLKL | P74T-E | Human | Esophagus | ESCC | 2.73e-02 | 1.59e-01 | 0.1479 |
197259 | MLKL | P75T-E | Human | Esophagus | ESCC | 2.39e-03 | 2.93e-01 | 0.1125 |
197259 | MLKL | P76T-E | Human | Esophagus | ESCC | 1.56e-06 | 8.48e-02 | 0.1207 |
197259 | MLKL | P80T-E | Human | Esophagus | ESCC | 4.27e-13 | 3.01e-01 | 0.155 |
197259 | MLKL | P83T-E | Human | Esophagus | ESCC | 3.10e-18 | 6.01e-01 | 0.1738 |
197259 | MLKL | P89T-E | Human | Esophagus | ESCC | 6.22e-09 | 5.13e-01 | 0.1752 |
197259 | MLKL | P107T-E | Human | Esophagus | ESCC | 1.12e-06 | 1.85e-01 | 0.171 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:00973002 | Esophagus | ESCC | programmed necrotic cell death | 32/8552 | 47/18723 | 1.59e-03 | 7.43e-03 | 32 |
GO:00512592 | Esophagus | ESCC | protein complex oligomerization | 130/8552 | 238/18723 | 3.29e-03 | 1.36e-02 | 130 |
GO:00702654 | Esophagus | ESCC | necrotic cell death | 39/8552 | 62/18723 | 4.68e-03 | 1.82e-02 | 39 |
GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa046234 | Esophagus | ESCC | Cytosolic DNA-sensing pathway | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa0466817 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa0462311 | Esophagus | ESCC | Cytosolic DNA-sensing pathway | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
hsa0513242 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
hsa046684 | Liver | HCC | TNF signaling pathway | 73/4020 | 114/8465 | 2.53e-04 | 1.19e-03 | 6.63e-04 | 73 |
hsa0513252 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
hsa0466811 | Liver | HCC | TNF signaling pathway | 73/4020 | 114/8465 | 2.53e-04 | 1.19e-03 | 6.63e-04 | 73 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MLKL | SNV | Missense_Mutation | novel | c.158T>C | p.Val53Ala | p.V53A | Q8NB16 | protein_coding | deleterious(0.01) | benign(0.026) | TCGA-AG-3726-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MLKL | SNV | Missense_Mutation | novel | c.265N>A | p.Leu89Ile | p.L89I | Q8NB16 | protein_coding | tolerated(0.11) | benign(0.195) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MLKL | SNV | Missense_Mutation | novel | c.361N>T | p.Arg121Cys | p.R121C | Q8NB16 | protein_coding | tolerated(0.09) | possibly_damaging(0.759) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MLKL | SNV | Missense_Mutation | novel | c.191N>A | p.Arg64His | p.R64H | Q8NB16 | protein_coding | tolerated(0.27) | possibly_damaging(0.613) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
MLKL | SNV | Missense_Mutation | novel | c.110G>C | p.Gly37Ala | p.G37A | Q8NB16 | protein_coding | tolerated(0.79) | benign(0.015) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MLKL | SNV | Missense_Mutation | c.527N>C | p.Leu176Ser | p.L176S | Q8NB16 | protein_coding | deleterious(0) | possibly_damaging(0.797) | TCGA-AP-A05N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MLKL | SNV | Missense_Mutation | c.1383N>C | p.Glu461Asp | p.E461D | Q8NB16 | protein_coding | tolerated(0.11) | benign(0.031) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
MLKL | SNV | Missense_Mutation | rs145083759 | c.988N>A | p.Gly330Arg | p.G330R | Q8NB16 | protein_coding | tolerated(0.91) | benign(0.03) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
MLKL | SNV | Missense_Mutation | novel | c.1216G>A | p.Ala406Thr | p.A406T | Q8NB16 | protein_coding | tolerated(0.08) | possibly_damaging(0.7) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MLKL | SNV | Missense_Mutation | rs748989197 | c.427N>A | p.Glu143Lys | p.E143K | Q8NB16 | protein_coding | tolerated(0.2) | possibly_damaging(0.603) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
197259 | MLKL | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE | inhibitor | 336446900 |
Page: 1 |